Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD) is an inherited disorder that belongs to a group of fatty acid oxidation disorders. It results from a defect in the enzyme acyl-CoA dehydrogenase, which is responsible for the oxidation of long-chain fatty acids, resulting in the accumulation of incomplete metabolites and a decrease in the body's ability to use fatty acids as an energy source. These processes can cause a variety of clinical manifestations, including hypoglycemia, myopathy, cardiomyopathy, and even life-threatening conditions such as acute metabolic crises. Clinical manifestations most often occur with physical stress, infections, or excessive intervals between meals.
History of the disease and interesting historical facts
Very long-chain acyl-CoA dehydrogenase deficiency was first described in the medical literature in the early 1990s, when serum enzyme assays and molecular genetics-based tests became available. In 1993, the first case of VLCAD in a child was reported, marking a turning point in the study of the disorder. Since then, numerous cases have been identified and studies have been conducted that have helped to establish the genetic basis of the condition. Research has shown that the disorder can manifest in a variety of forms, from asymptomatic to severe metabolic crises.
Epidemiology
The epidemiology of very long-chain acyl-CoA dehydrogenase deficiency varies from region to region. The incidence of VLCAD in newborns is estimated to be approximately 1 in 10,000 to 1 in 20,000 live births. Populations with a high incidence are more susceptible to the disorder. For example, northern European and Scandinavian populations have an increased incidence. Given the hereditary nature of the disorder, its prevalence may be higher in areas with high inbreeding.
Genetic predisposition to this disease
Very long-chain acyl-CoA dehydrogenase deficiency is caused by mutations in the ACADVL gene, located on chromosome 17q24. This gene encodes an enzyme involved in the metabolism of long-chain fatty acids. More than 100 different mutations in this gene have been identified and associated with disease manifestation. The most common mutations include, for example, nucleotide substitutions, deletions and insertions. Carriers of the mutation usually do not show clinical signs, but when inherited recessively, the disease manifests in offspring.
Risk factors for the development of this disease
Risk factors for VLCAD can be divided into several categories:
- Genetic factors: presence of mutations in the ACADVL gene.
- Family history: A history of the disease in the family increases the risk.
- Demographic factors: increased incidence of the disease among certain ethnic groups.
- Environmental factors: There is a possibility that the environment, especially chemicals, may influence fat metabolism, which may worsen the disease in existing carriers.
Diagnosis of this disease
Diagnosis of very long-chain acyl-CoA dehydrogenase deficiency includes:
- Main symptoms: hypoglycemia, myalgia, vomiting, dyspepsia, cardiac disorders.
- Laboratory tests: Metabolic screening, including urine analysis for organic acids and blood analysis for fatty acid levels.
- Radiological examinations: echocardiogram to assess cardiac function in cardiomyopathy.
- Other diagnostic tests include molecular genetic testing to identify mutations in the ACADVL gene.
- Differential diagnosis: exclusion of other fatty acid oxidation disorders and metabolic diseases.
Treatment
Treatment of VLCAD can be divided into several areas:
- General treatment: dietary modification with emphasis on carbohydrates and control of fat intake.
- Pharmacological treatment: use of carnitine to improve fatty acid oxidation.
- Surgery: In rare cases, surgery may be needed to correct secondary problems such as cardiomyopathy.
- Other treatments include physical therapy to support the muscle in myopathy and educational programs for families.
List of medications used to treat this disease
The main drugs used to treat very long-chain acyl-CoA dehydrogenase deficiency include:
- Coenzyme Q10 – to support energy metabolism.
- Carnitine – for transporting fatty acids into the mitochondria.
- Drugs that prevent hypoglycemia, including glucose.
Disease monitoring
Monitoring of patients with VLCAD includes:
- Control stages: regular monitoring of fatty acid levels and metabolic parameters.
- Prognosis: The presence and severity of heart and muscle disease can affect the overall prognosis.
- Complications: Complications such as cardiomyopathy and increased risk of infections if not adequately controlled may occur.
Age-related features of the disease
Age-related features of VLCAD manifestation may vary:
- Newborns: Often have severe symptoms that may require prompt medical attention.
- Children: risk of crises when blood sugar levels drop during physical exertion.
- Adults: May appear asymptomatic or have mild symptoms, but may suffer from chronic fatigue and weakness.
Questions and Answers
- What is very long chain acyl-CoA dehydrogenase deficiency? It is an inherited disorder associated with impaired oxidation of long-chain fatty acids, which can cause a variety of clinical manifestations and conditions.
- How is this disease diagnosed? Diagnosis includes laboratory tests, radioscans and molecular genetic testing.
- What are the risk factors for VLCAD? These include genetic predisposition, family history, and some environmental factors.
- How is very long chain acyl-CoA dehydrogenase deficiency treated? Treatment includes dietary changes, medications such as carnitine, and, in rare cases, surgery.
- What is the prognosis for patients with VLCAD? The prognosis varies depending on the severity of the condition and the presence of complications such as cardiomyopathy.
